UNC Collaborative for Maternal & Infant Health

UNC Collaborative for Maternal & Infant Health

Improving the health of North Carolina's women and infants

Search UNC Collaborative for Maternal & Infant Health

Menu
  • Home
  • About Us
    • Overview
    • Our Team
    • Collaborations & Partnerships
    • Internships
    • Newsletters
    • Legacy
    • Donate
    • Subscribe
    • Contact Us
    • Close
  • Key Services
    • Family-Centered Care
      • Care Coordination
      • Referrals to UNC
      • Special Infant Care Clinic
      • Prenatal Diagnosis and Fetal Therapy
      • Perinatal Loss
      • Clinic Partners
    • Technical Assistance
      • Preconception Health
      • Tobacco Resources
      • Health Information Services
    • Close
  • Patient Education Materials
  • Resources for Practice
    • OB Algorithms
    • UNC Internal Protocols
    • 17P (Progesterone)
    • UNC Lactation Program
    • CCNC PMH Care Pathways
    • NICU Clinical Guidelines
    • Trisomy 13 and Trisomy 18
    • Close
  • State and National Programs
    • Child Fatality Task Force / NC Perinatal Plan
    • Collaborative Improvement and Innovation Network on Infant Mortality (IM CoIIN)
    • Every Woman Southeast
    • ERASE Maternal Mortality-“I Gave Birth” Initiative
    • NC 17P Project
    • North Carolina Perinatal Region IV Provider Support Network
    • Perinatal/Neonatal Outreach Coordination (PNOC) project
    • Safe Sleep NC
    • You Quit, Two Quit
    • National Preconception Health & Health Care Initiative (PCHHC)
    • The North Carolina Perinatal Health and Incarceration Working Group
    • Close
  • Research
    • 4th Trimester Project
    • Bowes Cefalo Research Award
    • Care4Moms
    • Close
  • Search

Statement on FDA Advisory Committee Decision

In Oct 2019, a Food and Drug Administration advisory committee recommended that approval be withdrawn for Makena – 17-α-hydroxyprogesterone caproate or “17P.”  In Oct 2020, the FDA’s Center for Drug Evaluation and Research issued the recommendation that Makena and its generic equivalents be pulled from the market. There has not yet been a final decision, and Makena and generic 17P remain on the market.  Both the American College of Obstetrics and Gynecology and the Society for Maternal-Fetal Medicine have issued statements recommending no changes to the existing clinical guidance regarding 17P.  As recommended earlier, providers should engage in a framework of shared decision-making with at-risk patients to decide whether or not to use 17P.  Please see this handout for more information.

Click HERE to read new guidance from the Society for Maternal-Fetal Medicine (SMFM) regarding vaginal progesterone or 17P for preterm birth prevention.
Key take-away from new guidance:
Although the results of this study suggest that either 17-OHPC or vaginal progesterone appear to offer a benefit to women with a singleton gestation and either short cervix or prior sPTB, the certainty regarding the benefit, both maternal and neonatal, is greatest for vaginal progesterone.

Questions? Email Erin McClain.

Subscribe to Updates

UNC Collaborative for Maternal and Infant Health aims to improve the health and well-being of women and families across North Carolina through community partnerships, research and clinical care innovations, and developing new approaches to complex problems.

Contact Us

Room 216 MacNider
Campus Box 7181
Chapel Hill, NC 27599-7181

The University of North Carolina at Chapel Hill

Find Us

Info on visiting UNC Hospitals

Support Us

Donate Now

Connect With Us

  • Email
  • LinkedIn
  • Twitter

Copyright © 2023 UNC Center for Maternal & Infant Health · All Rights Reserved · Website by Tomatillo Design